Presenter of 10 Presentations
Welcome from EAS President
Young Investigator Award
Introduction to Anitschkow Prize winner, Prof Nordestgaard
Reimagining prevention: the population approach
An App to guide clinical care- what is it and how should we use it
What’s been achieved and what more is needed - real world evidence
The epidemiology of DM and obesity and risk of ASCVD
OBICETRAPIB LOWERS LDL-C IN PATIENTS ON HIGH INTENSITY STATINS: RESULTS FROM THE ROSE TRIAL (NCT04753606).
Background and Aims
Background: As guidelines now recommend lower LDL-C goals, means that many patients require additional lipid lowering therapies (LLT) to attain risk based LDL-C goals despite use of high intensity statins (HIS). Cost and/or efficacy of current LLT options have limited their uptake in clinical practice. Mendelian randomization and RCT trial data support CETP inhibition as a validated target to reduce LDL-C and cardiovascular risk. Safety and efficacy concerns have to date limited the development of CETPi. Previously the selective CETPi obicetrapib demonstrated LDL-C lowering up to 45% as monotherapy.
Aims: To assess the effects of obicetrapib on LDL-C and lipid parameters in patients on HIS.
Methods: 120 patients with LDL-C ≥70 mg/dL, despite HIS, were randomized to obicetrapib 5 or 10 mg or placebo for 8 weeks. The primary endpoint was percent change in LDL-C, secondary endpoints included changes in other lipids, exploratory analyses evaluated goal attainment.
Results: Obicetrapib produced dose-dependent lowering of LDL-C, ApoB and non-HDL-C (up to 50.8%, 29.8% and 44.4% respectively, P<0.0001 for each, Table). Approximately 2/3 of patients achieved LDL-C < 55mg/dl when Obicetrapib was added to HIS vs PL. Fewer patients in the OBI arms experienced treatment emergent adverse events vs placebo (26 vs 48%) with no clinically significant changes in laboratory parameters, vital signs, or physical examinations.
Conclusion: Obicetrapib 5 and 10 mg produced robust decreases in LDL-C, ApoB and Non-HDL-C with greater attainment of lipid goals in the majority of patients treated with HIS and was well tolerated.